Australia markets close in 5 hours 33 minutes

Lifeist Wellness Inc. (NXTTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0847-0.0022 (-2.53%)
At close: 03:34PM EST
Full screen
Loading interactive chart…
  • GlobeNewswire

    Lifeist’s Consumer-focused Roilty Brand Wins Coveted “Canadian LP Brand of Year” Award at ADCANN

    Continued Progress for Lifeist’s Cannabis Business in 2021 Roilty: 2021 Canadian LP Brand of the Year Lifeist’s Consumer-focused Roilty Brand Wins Coveted “Canadian LP Brand of Year” Award at ADCANN TORONTO, Jan. 14, 2022 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a health-tech company that leverages advancements in science and technology to enable you to find your path to wellness, today announced that its Cannabis 2.0

  • GlobeNewswire

    Lifeist Wellness Inc. Issues Long Term Incentives

    TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a health-tech company that leverages advancements in science and technology to enable you to find your path to wellness, today announced issuance of long-term incentives in favour of directors, officers and a former director of the Company. The board of directors of the Company (“Board”) recognises that long term incentives, vesting over multiple years, st

  • GlobeNewswire

    Lifeist Subsidiary Mikra Cellular Sciences to Launch First Product “CELLF” to Combat Brain Fog and Unlock Healthy Aging, Announces U.S. Patent Application and Pre-Clinical Study

    CELLF Single-serve Sachet (Image of CELLF single-serve sachet by Mikra Cellular Sciences) CELLF Product Package (Image of CELLF product package by Mikra Cellular Sciences) CELLF Product & Community Launch (Image of CELLF mobile marketing by Mikra Cellular Sciences) - Mikra patent focusing on novel cellular therapeutic targeting systemic fatigue- Mikra partners with InVivo Biosystems for pre-clinical trials to strengthen patent application and generate further data confirming expression pathways